ArticleAmerican journal of preventive cardiology2026
Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition. Incretin therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and emerging dual agonists, have shown promise in improving steatohepatitis. Objective: This study aims to evaluate the efficacy and safety of incretin therapies compared with standard therapies in patients with MASLD. Methods: Systematic search of Randomized Controlled Trials (RCTs) from database inception to August 2025 was done. Eligible RCTs enrolled adults with MASLD or biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH), comparing incretin therapies with placebo, oral hypoglycemic agents (OHAs), or insulin. Outcomes were changes in liver enzymes, liver fat, and fibrosis resolution. Results: Twenty-four RCTs (n = 2158) were included. Compared with placebo, incretin therapies reduced ALT (SMD -0.46; 95 % CI -0.67 to -0.25), AST (SMD -0.41; 95 % CI -0.66 to -0.17), and liver fat (SMD -0.55; 95 % CI -1.38 to 0.27). When compared to insulin, ALT (SMD -1.02; 95 % CI -1.98 to -0.05), AST (SMD -0.62; 95 % CI -1.21 to -0.04), and liver fat (SMD -0.62; 95 % CI -0.92 to -0.32) were significantly reduced. Incretin therapies improved non-invasive fibrosis markers. Steatohepatitis resolution was greater vs placebo but not insulin. Hepatic and steatohepatitis outcomes appeared greater among patients with diabetes. Conclusion: Incretin therapies improve liver enzymes, reduce liver fat, and promote steatohepatitis resolution in MASLD with an acceptable safety profile. Benefits may be greater in patients with coexisting diabetes. Effects on histologic fibrosis remain inconclusive, underscoring the need for larger and longer trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.